Quillichew is a Central Nervous System (CNS) Stimulant Medication
Quillichew ER (methylphenidate hydrochloride extended-release chewable tablets) is a psychostimulant medication classified as a Schedule II controlled substance, primarily used for treating Attention-Deficit/Hyperactivity Disorder (ADHD) in patients aged 6 years and older 1.
Drug Classification and Mechanism
Quillichew belongs to the methylphenidate class of psychostimulants 2. As a CNS stimulant, methylphenidate works by blocking the reuptake of norepinephrine and dopamine into presynaptic neurons while simultaneously increasing the release of these monoamines into the extraneuronal space 1. This sympathomimetic action directly stimulates adrenergic receptors as an agonist and indirectly causes neurotransmitter release from presynaptic terminals 3.
Formulation Characteristics
Quillichew ER is specifically formulated as an extended-release chewable tablet that contains approximately 30% immediate-release and 70% extended-release methylphenidate 1. The medication is available in three dosage strengths: 20 mg, 30 mg, and 40 mg 1. Notably, only 15% of the methylphenidate is present as methylphenidate hydrochloride salt, while the remaining 85% is ionically bound to sodium polystyrene sulfonate particles 1.
The chewable formulation reaches maximum plasma concentration (Cmax) at a median time of 5 hours after dosing, with a mean plasma terminal elimination half-life of approximately 5.2 hours 1. This extended-release profile allows for once-daily dosing, which can improve treatment adherence compared to immediate-release formulations that require multiple daily doses 4, 5.
Clinical Use Context
According to current ADHD treatment guidelines, methylphenidate formulations like Quillichew are recommended as first-line pharmacological treatment for ADHD 2. For elementary and middle school-aged children (ages 6-12 years), FDA-approved ADHD medications should be prescribed along with parent training in behavior management and/or behavioral classroom interventions 6. For adolescents (ages 12-18 years), FDA-approved medications should be prescribed with the adolescent's assent 6.
The 2024 Asian guidelines and 2019 AAP guidelines both classify methylphenidate products, including extended-release formulations, as stimulant medications that are FDA-approved for ADHD treatment in children and adolescents aged 6-17 years 2.
Controlled Substance Status
Quillichew is classified as a Schedule II controlled substance due to its potential for abuse and dependence 1. Methylphenidate and other psychostimulants are scheduled as controlled drugs because of their rapid onset of action, immediate behavioral effects, and tendency to develop tolerance with continued use, which increases the risk for abuse and dependence in vulnerable individuals 3.
The medication carries a boxed warning regarding CNS stimulant abuse and dependence, noting that misuse can result in overdose and death, with this risk increased at higher doses or with unapproved methods of administration such as snorting or injection 1.
Safety Considerations
Common side effects include agitation, insomnia, decreased appetite, headache, and gastrointestinal symptoms 3. Rare but serious side effects include hypertension, palpitations, arrhythmias, confusion, psychosis, and cardiovascular events 3. Methylphenidate should be avoided in patients with uncontrolled hypertension, underlying coronary artery disease, and tachyarrhythmias 3.
The chewable formulation contains aspartame and should be used with caution in patients with phenylketonuria 1.